Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Issue 7 (30th April 2019)

• Record Type: Journal Article
• Authors: Tanaka, Yoshiya; Fautrel, Bruno; Keystone, Edward C; Ortmann, Robert A; Xie, Li; Zhu, Baojin; Issa, Maher; Patel, Himanshu; Gaich, Carol L; de Bono, Stephanie; Rooney, Terence P; Taylor, Peter C
• Is Part Of: Annals of the rheumatic diseases. Volume 78:Issue 7(2019)
• Page Start: 890
• Page End: 898
• Publication Date: 2019-04-30
• Subjects: rheumatoid arthritis -- dmards (biologics) -- jak inhibitor; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-214529
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: To evaluate clinical outcomes in patients who changed treatment from adalimumab to baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, during a phase III programme. Methods: In phase III RA-BEAM, patients were randomised 3:3:2 to placebo, baricitinib 4 mg once daily, or adalimumab 40 mg biweekly. At week 16 or subsequent visits, non-responders were rescued to open-label baricitinib 4 mg. At week 52, patients could enter a long-term extension (LTE) and continue on baricitinib or switch from adalimumab to baricitinib 4 mg with no adalimumab washout period. Percentage of patients achieving low disease activity and remission were assessed, along with physical function, patient's assessment of pain, and safety. Results: Thirty-five (7%) baricitinib-treated and 40 (12%) adalimumab-treated patients were rescued to baricitinib in RA-BEAM; 78% (381/487) of baricitinib-treated and 72% (238/330) of adalimumab-treated patients who were not rescued in RA-BEAM, entered the LTE and continued/were switched to baricitinib. In both baricitinib-rescued and adalimumab-rescued patients, there were significant improvements in all measures up to 12 weeks after rescue compared with the time of rescue. Patients who switched from adalimumab to baricitinib showed improvements in disease control through 12 weeks in the LTE. Exposure-adjusted incidence rates for treatment-emergent adverse events (TEAEs) and infections, including serious events, were similar for patients who switched from adalimumab to baricitinib and those who continued on baricitinib. Conclusions: Switching from adalimumab to baricitinib (without adalimumab washout) was associated with improvements in disease control, physical function and pain during the initial 12 weeks postswitch, without an increase in TEAEs, serious adverse events or infections. Trial registration numbers: NCT01710358, NCT01885078 .